Lilly Published Results of Tirzepatide in SURPASS-4 Study for the Treatment of Type 2 Diabetes in The Lancet
Shots:
- The SURPASS-4 study evaluates the efficacy & safety of tirzepatide (5/10/15mg) vs insulin glargine in 2002 adults in a ratio (1:1:1:3) with T2D inadequately controlled with 1 & up to 3 oral antihyperglycemic medications who have increased CV risk
- The study met its 1EPs & 2EPs i.e.- superior A1C & body weight reductions for both estimands @52wks. A1C reduction (-2.24% / -2.43%/ -2.58% vs -1.44%); weight reduction (-7.1/ -9.5/ -11.7kg vs +1.9 kg); patients achieving A1C <7% (81%/ 88%/ 91% vs 51%); patients achieving A1C <5.7% (23%/ 33%/ 43% vs 3%) respectively
- Additionally- the overall safety profile was consistent with safety results @52wks. & no new findings were observed @~104 weeks.
| Ref: PR Newswire | Image: The Indian Express
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com